Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.45 EUR | +1.05% | +0.69% | -7.94% |
Mar. 06 | Herantis Pharma Oyj Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 06 | Transcript : Herantis Pharma Oyj, 2023 Earnings Call, Mar 06, 2024 |
Sales 2024 * | 1.3M 1.41M | Sales 2025 * | - | Capitalization | 29.23M 31.65M |
---|---|---|---|---|---|
Net income 2024 * | -3M -3.25M | Net income 2025 * | -4M -4.33M | EV / Sales 2024 * | 19.3 x |
Net cash position 2024 * | 4.2M 4.55M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 10 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 69.93% |
Latest transcript on Herantis Pharma Oyj
1 day | +1.05% | ||
1 week | +0.69% | ||
Current month | +3.57% | ||
1 month | +3.57% | ||
3 months | +3.57% | ||
6 months | -19.44% | ||
Current year | -7.94% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 07-12-31 | |
Antti Vuolanto
CEO | Chief Executive Officer | - | 18-02-11 |
Tone Kvåle
DFI | Director of Finance/CFO | 55 | 20-10-25 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 53 | 13-12-31 | |
Director/Board Member | 53 | 20-03-10 | |
Chairman | 64 | 11-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 1.45 | +1.05% | 81,098 |
24-05-13 | 1.435 | -1.03% | 15,201 |
24-05-10 | 1.45 | +2.11% | 10,780 |
24-05-08 | 1.42 | -1.39% | 1,036 |
24-05-07 | 1.44 | +1.77% | 4,551 |
Delayed Quote Nasdaq Helsinki, May 14, 2024 at 11:02 am EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-7.94% | 31.23M | |
+5.33% | 111B | |
+12.11% | 105B | |
-12.56% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.86% | 16.96B | |
+5.10% | 13.7B | |
+37.57% | 12.45B |
- Stock Market
- Equities
- HRTIS Stock